These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12597158)

  • 21. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
    Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
    Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
    Hilgenbrink AR; Low PS
    J Pharm Sci; 2005 Oct; 94(10):2135-46. PubMed ID: 16136558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiologists urge FDA to accept PET-based tumor response criteria in clinical trials.
    Brower V
    J Natl Cancer Inst; 2011 Apr; 103(8):622-4. PubMed ID: 21474833
    [No Abstract]   [Full Text] [Related]  

  • 24. Validation of analytic methods for biomarkers used in drug development.
    Chau CH; Rixe O; McLeod H; Figg WD
    Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
    Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of cancer gene panels with OncoPaD.
    Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
    Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NMR-based metabolomics: translational application and treatment of cancer.
    Serkova NJ; Spratlin JL; Eckhardt SG
    Curr Opin Mol Ther; 2007 Dec; 9(6):572-85. PubMed ID: 18041668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma.
    Di Lorenzo G; Buonerba C
    Future Oncol; 2016 Feb; 12(3):277-9. PubMed ID: 26768297
    [No Abstract]   [Full Text] [Related]  

  • 30. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
    Rubio-Viqueira B; Hidalgo M
    Clin Pharmacol Ther; 2009 Feb; 85(2):217-21. PubMed ID: 19005462
    [No Abstract]   [Full Text] [Related]  

  • 31. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer.
    Amin S; Bathe OF
    BMC Cancer; 2016 Nov; 16(1):850. PubMed ID: 27814715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Targeted therapy: old and new possibilities].
    Hochhaus A; Lüftner D; Mackensen A
    Onkologie; 2013; 36 Suppl 5():2-11. PubMed ID: 23921800
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.
    Indovina P; Pentimalli F; Casini N; Vocca I; Giordano A
    Oncotarget; 2015 Jul; 6(20):17873-90. PubMed ID: 26160835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 36. The search for optimal response prediction in cancer leads to a personalized approach.
    Van Cutsem E; Ciardiello F
    Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
    [No Abstract]   [Full Text] [Related]  

  • 37. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.